KLOR-CON M15
Clinical safety rating: caution
Comprehensive clinical and safety monograph for KLOR-CON M15 (KLOR-CON M15).
Potassium is the major intracellular cation; it is necessary for conduction of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, maintenance of normal renal function, acid-base balance, and carbohydrate metabolism.
| Metabolism | Not metabolized; excreted primarily by the kidneys. |
| Excretion | Renal: >90% as potassium ions; fecal: <5%; biliary: negligible. |
| Half-life | Not applicable; potassium is not eliminated by first-order kinetics. Serum potassium decline depends on redistribution and renal function, with a half-life of approximately 1-1.5 hours for acute redistribution but prolonged in renal impairment. |
| Protein binding | Potassium is not significantly bound to plasma proteins; <2% bound. |
| Volume of Distribution | Approximately 0.5 L/kg (total body water); distributes primarily intracellularly (98% of total body potassium is intracellular). |
| Bioavailability | Oral: 100% (potassium chloride is fully absorbed from the gastrointestinal tract). |
| Onset of Action | Oral: 30–60 minutes for rise in serum potassium; peak effect at 2–4 hours. |
| Duration of Action | Oral: Serum potassium elevation persists for 4–6 hours after a single dose; sustained-release formulations (e.g., M15) provide gradual release over 8–12 hours. |
Oral: 15 mEq (1 tablet) once daily or as directed; range 15-100 mEq/day divided doses. Maximum 150 mEq/day.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | eGFR 30-59 mL/min: initiate cautiously, monitor serum potassium; eGFR <30 mL/min: contraindicated due to risk of hyperkalemia. |
| Liver impairment | No specific guidelines; use with caution in severe impairment due to potential electrolyte disturbances. |
| Pediatric use | Oral: 1-2 mEq/kg/day divided doses; maximum 3 mEq/kg/day (not to exceed 100 mEq/day). Dose based on serum potassium levels. |
| Geriatric use | Initiate at low end of dosing range (15-30 mEq/day) due to age-related renal decline; monitor renal function and potassium levels. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for KLOR-CON M15 (KLOR-CON M15).
| Breastfeeding | Potassium chloride is excreted into breast milk; M/P ratio not established. Use with caution, monitor infant potassium levels. |
| Teratogenic Risk | Potassium chloride is not teratogenic in animal studies. No well-controlled human studies exist. Risk of hyperkalemia in the mother may affect fetus (e.g., cardiac arrhythmias). Use only if clearly needed. |
| Fetal Monitoring |
■ FDA Black Box Warning
Potassium chloride supplements can cause hyperkalemia and cardiac arrest. Do not use with potassium-sparing diuretics or in patients with conditions predisposing to hyperkalemia.
| Serious Effects |
["Hyperkalemia","Severe renal failure with oliguria or azotemia","Addison's disease","Concurrent use of potassium-sparing diuretics or ACE inhibitors","Conditions involving high potassium levels (e.g., systemic acidosis, extensive tissue breakdown)","Use of solid oral dosage forms in patients with gastrointestinal obstruction or delayed transit"]
| Precautions | ["Risk of hyperkalemia, especially in patients with renal impairment, diabetes, or elderly","Gastrointestinal irritation and ulceration; use wax-matrix formulations to reduce risk","Avoid in severe renal insufficiency, uncontrolled adrenal insufficiency, acute dehydration, or extensive tissue breakdown","Monitor serum potassium levels and ECG during therapy"] |
Loading safety data…
| Monitor serum potassium, renal function, ECG for arrhythmias, fetal heart rate if hyperkalemia suspected. |
| Fertility Effects | No known effects on fertility. |